2nd quarter and first half 2019 report

15. Aug 2019 | 3 min read


Moss 15.08.19

Gentian Diagnostics AS announces its results for the second quarter and first half of 2019.
The highlights include:
  • 16 % growth in sales revenue in 2Q19 compared to 2Q18
  • Total sales revenues of MNOK 10.2 in 2Q19, up from MNOK 8.8 in 2Q18
  • FDA 510(k) clearance for the BÜHLMANN fCAL® turbo and with this access to the US market
  • In July, Beckman Coulter, one of the top 5 global diagnostics companies, and Gentian have prolongated the trusted partnership agreement by another 6 years
  • In August, Gentian announced the sales channel agreement for fCAL® turbo between Roche Diagnostics and Gentian’s sales partner Bühlmann Laboratories AG


Please find the report and results presentation enclosed:

GDAS 2019 1H interim report

GDAS 2019 1H interim presentation


For further information, please contact:

Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242

Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525


MeldingsID: 482926


You may also read